IASO 782
Alternative Names: IASO-782Latest Information Update: 29 Jul 2024
At a glance
- Originator Nanjing IASO Biotechnology
- Class Antianaemics; Antihaemorrhagics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD19 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haemolytic anaemia; Thrombocytopenia
Most Recent Events
- 25 Jul 2024 National Medical Products Administration (NMPA) approves IND application for IASO 782 in Systemic lupus erythematosus (SLE) .
- 25 Jul 2024 IASO Bio plans a clinical trial in Systemic lupus erythematosus (Parenteral, injection)
- 17 Jun 2023 Preclinical trials in Haemolytic anaemia in China (Parenteral)